NeoImmuneTech, Inc. (NIT or “NeoImmuneTech”), a clinical-stage T cell-focused biopharmaceutical company, today announced the opening of a new section of its corporate website (link to ESG website) dedicated to the company policies and activities related to Environmental, Social, and Governance (ESG) matters.
ESG analysis has become an increasingly important part of any investment process and there is a growing demand for sustainable management across all sectors. Despite this increased importance, a large majority of Biotech companies do not provide related information.1 In an effort to anticipate the market evolution, and to fully align its activities with its values, NIT has created a whole section on its website that describes the company’s ESG activities.
Dr. Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech said: “As a biotech company that strives to positively impact human life by creating and developing a next generation of immunology therapy, we believe we have a moral responsibility to respect the global ESG standards. Beyond disclosing our policies, we will continue to develop and apply our ESG strategies across all our activities so that we strengthen our company as a sustainable business”.
1 Biotech’s ESG Crossroads. Fenwick report. Feb 2022
*** ENDS ***
About NeoImmuneTech, Inc.
NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases. NIT is led by the scientific founder and inventor of NT-I7 (efineptakin alfa) and has a strong executive team with rich industry experience. NIT is expanding rapidly in personnel and operations, as well as partnering with industry and academic leaders to investigate NT-I7 as monotherapy and in combination with various immunotherapeutics. For more information, please visit www.neoimmunetech.com.
Media inquiries : email@example.com